S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
These are the Top 4 Stocks for Buybacks in 2024
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
These are the Top 4 Stocks for Buybacks in 2024
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
These are the Top 4 Stocks for Buybacks in 2024
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
These are the Top 4 Stocks for Buybacks in 2024
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China

Avalo Therapeutics (AVTX) Competitors

$12.01
-1.61 (-11.82%)
(As of 04/18/2024 ET)

AVTX vs. AYTU, PIRS, NRBO, ORGS, TLPH, NERV, COCP, VBIV, TRAW, and GLTO

Should you be buying Avalo Therapeutics stock or one of its competitors? The main competitors of Avalo Therapeutics include Aytu BioPharma (AYTU), Pieris Pharmaceuticals (PIRS), NeuroBo Pharmaceuticals (NRBO), Orgenesis (ORGS), Talphera (TLPH), Minerva Neurosciences (NERV), Cocrystal Pharma (COCP), VBI Vaccines (VBIV), Traws Pharma (TRAW), and Galecto (GLTO). These companies are all part of the "medical" sector.

Avalo Therapeutics vs.

Aytu BioPharma (NASDAQ:AYTU) and Avalo Therapeutics (NASDAQ:AVTX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, media sentiment, analyst recommendations, profitability, risk, community ranking, dividends and earnings.

Aytu BioPharma has a net margin of -18.27% compared to Aytu BioPharma's net margin of -1,639.50%. Avalo Therapeutics' return on equity of -41.00% beat Aytu BioPharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Aytu BioPharma-18.27% -41.00% -10.87%
Avalo Therapeutics -1,639.50%-1,439.87%-113.95%

Aytu BioPharma has a beta of -1.21, meaning that its stock price is 221% less volatile than the S&P 500. Comparatively, Avalo Therapeutics has a beta of 1.15, meaning that its stock price is 15% more volatile than the S&P 500.

33.5% of Aytu BioPharma shares are owned by institutional investors. Comparatively, 87.1% of Avalo Therapeutics shares are owned by institutional investors. 4.3% of Aytu BioPharma shares are owned by company insiders. Comparatively, 0.2% of Avalo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Avalo Therapeutics had 3 more articles in the media than Aytu BioPharma. MarketBeat recorded 4 mentions for Avalo Therapeutics and 1 mentions for Aytu BioPharma. Aytu BioPharma's average media sentiment score of 0.64 beat Avalo Therapeutics' score of 0.00 indicating that Avalo Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Aytu BioPharma
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Avalo Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Aytu BioPharma has higher revenue and earnings than Avalo Therapeutics. Aytu BioPharma is trading at a lower price-to-earnings ratio than Avalo Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aytu BioPharma$107.40M0.15-$17.05M-$4.04-0.71
Avalo Therapeutics$1.92M7.31-$31.54M-$616.67-0.02

Aytu BioPharma currently has a consensus price target of $5.00, suggesting a potential upside of 74.02%. Given Avalo Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Aytu BioPharma is more favorable than Avalo Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aytu BioPharma
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Avalo Therapeutics
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.50

Aytu BioPharma received 250 more outperform votes than Avalo Therapeutics when rated by MarketBeat users. Likewise, 67.11% of users gave Aytu BioPharma an outperform vote while only 31.25% of users gave Avalo Therapeutics an outperform vote.

CompanyUnderperformOutperform
Aytu BioPharmaOutperform Votes
255
67.11%
Underperform Votes
125
32.89%
Avalo TherapeuticsOutperform Votes
5
31.25%
Underperform Votes
11
68.75%

Summary

Aytu BioPharma beats Avalo Therapeutics on 11 of the 17 factors compared between the two stocks.

Get Avalo Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for AVTX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AVTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AVTX vs. The Competition

MetricAvalo TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$16.48M$6.44B$4.78B$7.47B
Dividend YieldN/A3.13%2.98%3.99%
P/E Ratio-0.027.34182.7014.17
Price / Sales7.31309.072,530.7687.68
Price / CashN/A29.7046.9535.12
Price / Book1.505.334.624.19
Net Income-$31.54M$142.19M$102.17M$212.33M
7 Day Performance-13.52%-7.31%-4.74%-4.60%
1 Month Performance206.76%-6.31%-4.30%-3.16%
1 Year Performance-97.99%-3.14%10.36%4.59%

Avalo Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AYTU
Aytu BioPharma
2.4106 of 5 stars
$2.92
+9.0%
$5.00
+71.2%
+6.0%$16.26M$107.40M-0.72150News Coverage
PIRS
Pieris Pharmaceuticals
0 of 5 stars
$0.16
-5.7%
N/A-81.0%$16.23M$42.81M-0.59127Gap Up
NRBO
NeuroBo Pharmaceuticals
0.6779 of 5 stars
$3.40
-3.7%
N/A-47.9%$16.69MN/A0.002News Coverage
Gap Up
ORGS
Orgenesis
1.7998 of 5 stars
$0.50
flat
N/A-56.2%$15.94M$36.03M-0.55167News Coverage
TLPH
Talphera
1.2465 of 5 stars
$1.02
flat
$6.00
+488.2%
N/A$17.31M$650,000.00-0.6915
NERV
Minerva Neurosciences
3.0969 of 5 stars
$2.50
+3.3%
$11.00
+340.0%
-10.5%$17.48MN/A-0.549Positive News
Gap Down
COCP
Cocrystal Pharma
2.5303 of 5 stars
$1.46
+3.5%
$10.00
+584.9%
-43.7%$14.85MN/A-0.7312Gap Up
VBIV
VBI Vaccines
1.2752 of 5 stars
$0.62
+6.9%
N/A-83.3%$14.69M$1.08M-0.05190Analyst Report
Gap Down
TRAW
Traws Pharma
0 of 5 stars
$0.70
-2.8%
N/AN/A$14.62M$230,000.00-0.76N/AGap Up
GLTO
Galecto
1.4083 of 5 stars
$0.68
-1.5%
$5.33
+686.2%
-67.4%$18.39MN/A-0.4713News Coverage
Gap Down

Related Companies and Tools

This page (NASDAQ:AVTX) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners